Objective: To investigate the effect of Chaihu Shugan San on memory function in Alzheimer's disease (AD)rats. Method: Rats were randomly divided into six groups

including the model group (C)

Chaihu Shugan San low-dose and high dose group (D

E)

kidney group (F) are used by D-galactose and β-protein(Aβ) hippocampus co-injection modeling

Aβ after the success of modeling the first 9 d

D

E groups were given ig Chaihu Shugan San 10

20 g·kg-1

F group was given Naolibao 20 g·kg-1. Each group were 9 : 00 in the morning by 10 mL·kg-1 ig administration of volume

continuous ig 28 d. ig before and after the water maze behavioral testing

the last animals were killed for hippocampus-related indicators messenger RNA (mRNA) expression relative determination. Result: Chaihu Shugan San maze before and after high-dose group ig time finding the platform

respectively (17.34±3.35)

(12.78±2.54) s

kidney groups were (17.79±2.25)

(14.11±2.66) s

before and after the two groups of ig and ig with the same period in the model group

there was a significant difference(P<0.01). After administration of the two groups hippocampal protein phosphatase-2A (PP-2A) mRNA expression values were (0.230 4±0.035)

(0.199 4±0.022 2)

with the model group(0.099±0.028 8) more significantly increased (P<0.01)

and cell cycle-dependent protein kinase 5 (CDK-5) and glycogen synthase kinase 3β (GSK- 3β) mRNA expression in high-dose group

kidney and high-dose group

low dose group were significantly lower (P<0.01). Conclusion: Chaihu Shugan San hippocampus by inhibiting GSK-3β

CDK-5 expression enhanced the expression of PP-2A

can reverse the Aβ-induced tau protein hyperphosphorylation

and thus the memory

cognitive disorders play a positive regulatory the role.